


 Substitute Form PTO-1449
(Modified)

 U.S. Department of Commerce
Patent and Trademark Office

 Attorney's Docket No.
06275-188002

Application No.

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

37 CFR §1.98(b)

 Applicant
Tommy Ekstrom

 Filing Date
Herewith

Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
KC	AD	0 416 950 A1	03/13/91	Europe				
KC	AE	0 416 951 A1	03/13/91	Europe				
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
KC	AG	Ankerst <i>et al.</i> , "Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma," <i>Pulm Pharmacol Ther.</i> , 16:147-51, 2003.
KC	AH	"The British Guidelines on Asthma Management 1995 Review and Position Statement," <i>Thorax</i> , 52(Suppl. 1):S1-21, 1997.
KC	AI	Collins <i>et al.</i> , "The Use of Corticosteroids in the Treatment of Acute Asthma," <i>Quarterly Journal of Medicine</i> , New Series, XLIV:259-73, 1975.
KC	AJ	Devidayal <i>et al.</i> , "Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma," <i>Acta Paediatr</i> , 88:835-840, 1999.
KC	AK	Ellul-Micallef and Johansson, "Acute Dose-Response Studies in Bronchial Asthma with a New Corticosteroid, Budesonide," <i>Br. J. Clin. Pharmac.</i> , 15:419-422, 1983.
KC	AL	Ellul-Micallef <i>et al.</i> , "Budesonide: A New Corticosteroid in Bronchial Asthma," <i>Eur J Respir Dis.</i> , 61:167-173, 1980.
KC	AM	Engel <i>et al.</i> , "Single-dose inhaled budesonide in subjects with chronic asthma," <i>Allergy</i> , 46:547-553, 1991.
KC	AN	Fanta <i>et al.</i> , "Glucocorticoids in Acute Asthma," <i>American Journal of Medicine</i> , 74:845-851, 1983.
KC	AO	Hett <i>et al.</i> , "Large-Scale Synthesis of Enanti- and Diastereomerically Pure (R,R)-Formoterol," <i>Org. Process Res. Dev.</i> , 2:96-99, 1998.
KC	AP	Li, "Key Points of the new asthma guidelines," <i>The Journal of Respiratory Diseases</i> , 18:823-838, 1997.
KC	AQ	Maesen <i>et al.</i> , "Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours," <i>Chest</i> , 97:590-4, 1990.
KC	AR	Maesen <i>et al.</i> , "Formoterol in the treatment of Nocturnal Asthma," <i>Chest</i> , 98:866-870, 1990.
KC	AS	Marsac <i>et al.</i> , "Inhaled beta adrenergic agonists and inhaled steroids in the treatment of asthma" <i>Annals of Allergy</i> , 63:220-224, 1989.

Examiner Signature

/Kendra Carter/

Date Considered

01/29/2007

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-188002	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant Tommy Ekstrom	
		Filing Date Herewith	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
KC	AT	Nana <i>et al.</i> , "High-Dose Inhaled Budesonide May Substitute for Oral Therapy After an Acute Asthma Attack," Journal of Asthma, 35:647-655, 1998.
KC	AU	National Asthma Education and Prevention Program, "Guidelines for the Diagnosis and Management of Asthma," Expert Panel Report 2 July 1997 No. 97-4051.
KC	AV	The Patents Act 1953 Statutory Declaration of Charles Richard William Beasley.
KC	AW	The Patents Act 1953 Exhibit "CRWB1."
KC	AX	The Patents Act 1953 Exhibit "CRWB3."
KC	AY	The Patents Act 1953 Exhibit "CRWB4."
KC	AZ	The Patents Act 1953 Exhibit "CRWB5."
KC	AAA	The Patents Act 1953 Exhibit "CRWB6."
KC	ABB	Pauwels <i>et al.</i> , "Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma," The New England J. of Medicine, 337:1405-1411, 1997.
KC	ACC	Poitiek <i>et al.</i> , "Comparison of formoterol, salsbutamol and salmeterol in methacholine-induced severe bronchoconstriction" B ₂ -Agonists In Methacholine-Induced Bronchoconstriction Eur Respir J., 13:988-992, 1999.
KC	ADD	Resenborg <i>et al.</i> , "Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics," Eur J. Clin Pharmacol., 56:363-370, 2000.
KC	AEE	Ryrfeldt <i>et al.</i> , "Pulmonary disposition of the potent glucocorticoid budesonide evaluated in an isolated perfused rat lung model," Biochem Pharmacol., 38:17-22, 1989.
KC	AFF	Schuh <i>et al.</i> , "A Comparison of Inhaled Fluticasone and Oral Prednisone For Children with Severe Acute Asthma," New England Journal of Medicine, 343:689-694, 2000.
KC	AGG	Sue <i>et al.</i> , "A Comparison of Intravenous Hydrocortisone, Methylprednisolone, And Dexamethasone in Acute Bronchial Asthma," Annals of Allergy, 56:406-409, 1986.
KC	AHH	Sykes <i>et al.</i> , "A study of the duration of the bronchodilator effect of 12 ug and 24 ug of inhaled formoterol and 200 ug inhaled salbutamol in asthma," Respir. Med., 84:135-138, 1990.
KC	AII	Tattersfield <i>et al.</i> on behalf of the Facet International Study Group, "Exacerbations of Asthma," Am J Respir Crit Care Med, 160:594-599, 1999.
KC	AJJ	U.S. Department of Health and Human services, "Practical Guide for the Diagnosis and Management of Asthma," October 1997 NIH Publication No. 97-4053.
KC	AKK	Vanieleghem <i>et al.</i> , "A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweed-induced rhinitis," J. Allergy Clin. Immunology, 79:887-892, 1987.

Examiner Signature /Kendra Carter/	Date Considered 01/29/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

9/3/2003

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Alicia Peterson
		Art Unit	
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	02-01	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KC		US- 6374811 B1	04-23-2002	Mancini	
KC		US- 6343590 B1	02-05-2002	Nagai et al.	
KC		US- 6302144 B1	10-16-2001	Graham et al.	
KC		US- 6237574 B1	05-29-2001	Jamrog et al.	
KC		US- 6136075	10-24-2000	Bragg et al.	
KC		US- 5957114	09-28-1999	Johnson et al.	
KC		US- 5924410	07-20-1999	Dumas et al.	
KC		US- 5651349	07-29-1997	Dykstra et al.	
KC		US- 5511957	04-30-1996	Tuckey et al.	
KC		US- 5408977	04-25-1995	Cotton	
KC		US- 4203401	05-20-1980	Kingsley et al.	
KC		US- 5119791	06-09-1992	Gifford et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

Examiner Signature	Kendra Carter	Date Considered	12/22/06
--------------------	---------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.